Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

OCUL Ocular Therapeutix Inc

NASDAQ

$10.04

Ocular Therapeutix Inc (OCUL) Earnings News

Earnings press releases and Earnings Whispers previews for Ocular Therapeutix Inc (OCUL), newest first.

Monday August 3, 2026 7:00 AM ET

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Wednesday June 17, 2026 8:45 AM ET

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Tuesday May 5, 2026 7:00 AM ET

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Tuesday April 28, 2026 7:00 AM ET

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Monday February 23, 2026 7:00 AM ET

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations